PASG Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

5.060

Open

4.670

VWAP

4.89

Vol

68.29K

Mkt Cap

16.06M

Low

4.600

Amount

333.70K

EV/EBITDA(TTM)

Total Shares

3.21M

-18.24M

EV/OCF(TTM)

P/S(TTM)

Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It also has a preclinical research program that explores multiple potential treatment targets for Huntington's disease.

Events Timeline

(ET)

2026-06-24

16:30:00

Passage Bio Trading Halted, News Pending

2026-06-24

16:30:00

Passage Bio and Remix Therapeutics Enter Merger Agreement

News

8.5

06-26NASDAQ.COM

Biotech Sector Update: FDA and EU Approvals

8.5

06-25NASDAQ.COM

Passage Bio and Remix Therapeutics Announce Merger Agreement

2.0

06-25stocktwits

ARS Pharmaceuticals Faces Insurance Coverage Setback

8.5

06-24stocktwits

Remix and Passage Bio Merger Details Unveiled

8.5

06-24seekingalpha

Passage Bio and Remix Therapeutics Announce Merger Agreement

9.5

03-03seekingalpha

Passage Bio Reports Q4 2025 Financial Results

3 Analyst Rating

Wall Street analysts forecast PASG stock price to rise

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

21.00

Averages

40.33

High

68.00

Current: 0.000

Low

21.00

Averages

40.33

High

68.00

Wedbush

Yun Zhong

Outperform

Neutral

downgrade

$32 -> $8

AI Analysis

2026-04-21

Reason

Wedbush

Yun Zhong

Price Target

$32 -> $8

AI Analysis

2026-04-21

downgrade

Outperform

Neutral

Reason

As previously reported, Wedbush analyst Yun Zhong downgraded Passage Bio to Neutral from Outperform with a price target of $8, down from $32. The firm cites Monday's regulatory update that a randomized controlled registrational study will be required to support PBFT02's FDA approval for the treatment of FTD-GRN. Although the ongoing Phase 1/2 upliFT-D study remains open, given that Passage Bio plans to explore all possible options to maximize shareholder value, Wedbush has conservatively removed the PBFT02 program from its valuation.

TD Cowen

Yaron Werber

Buy

Hold

downgrade

2026-04-21

Reason

TD Cowen

Yaron Werber

Price Target

2026-04-21

downgrade

Buy

Hold

Reason

TD Cowen analyst Yaron Werber downgraded Passage Bio to Hold from Buy with no price target after the company released updated Phase 1/2 frontotemporal dementia with granulin mutations data in line with prior updates, but also confirmed the FDA will require a randomized, placebo-controlled registrational study for PBFT02. Given that this removes a potentially expedited path to market in FTD-GRN, the firm sees the future of PBFT02 as \"uncertain,\" the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PASG

Unlock Now

Valuation Metrics

The current forward P/E ratio for Passage Bio Inc (PASG.O) is 0.00, compared to its 5-year average forward P/E of -1.07. For a more detailed relative valuation and DCF analysis to assess Passage Bio Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.07

Current PE

0.00

Overvalued PE

-0.33

Undervalued PE

-1.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.44

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.08

Undervalued EV/EBITDA

-0.20

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1.83

Current PS

0.00

Overvalued PS

8.13

Undervalued PS

-4.47

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

most bullish ticker

Intellectia · 46 candidates

Analyst Consensus: Strong BuyTarget Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA200Option Sentiments: BullishOne Week Rise Prob: >= 70

Ticker

Name

Market Cap$

TARS

Tarsus Pharmaceuticals Inc

2.78B

DERM

Journey Medical Corp

276.86M

CYTK

Cytokinetics Inc

7.93B

ABCL

Abcellera Biologics Inc

1.19B

SVRA

Savara Inc

1.16B

TSHA

Taysha Gene Therapies Inc

1.29B

current bearish stocks using patterns

Intellectia · 18 candidates

Gap Pattern: GapDownMoving Average Relationship: PriceBelowMA5, PriceBelowMA20Candlestick Pattern: DescendingTriangle, HeadAndShoulder, BlackCandlestickSupport Resistance Relationship: PriceFallBelowSupport

Ticker

Name

Market Cap$

MRT

Marti Technologies Inc

185.35M

BRLT

Brilliant Earth Group Inc

162.18M

SUIG

SUI Group Holdings Ltd

145.37M

WRAP

Wrap Technologies Inc

127.33M

TORO

Toro Corp

121.18M

ALGS

Aligos Therapeutics Inc

49.23M

Whales Holding PASG

Trading Trends

People Also Watch

Frequently Asked Questions

What is Passage Bio Inc (PASG) stock price today?

The current price of PASG is 5 USD — it has increased 6.38

What is Passage Bio Inc (PASG)'s business?

What is the price predicton of PASG Stock?

Wall Street analysts forecast PASG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PASG is40.33 USD with a low forecast of 21.00 USD and a high forecast of 68.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.